|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||86.79 - 87.73|
|52 Week Range||70.76 - 87.73|
|PE Ratio (TTM)||31.07|
|Forward Dividend & Yield||2.72 (3.12%)|
|1y Target Est||93.00|
Novartis AG said its fourth-quarter pretax profit increased on higher income from associated companies and strong sales of newer drugs, which helped offset the impact of generic competition.
Novartis AG starts 2018 with a new chief executive and a rosier outlook, projecting a return to growth after three lackluster years.
Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,
In January 2018, the U.S. FDA (Food and Drug Administration) accepted Novartis’s (NVS) supplemental biologics license application (or SBLA) for Kymriah suspension for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) who are not candidates for autologous stem cell transplant (or ASCT). The U.S. FDA granted Novartis’s sBLA for priority review. Also, the European Medicines Agency (or EMA) granted accelerated assessment to the marketing authorization application (or MAA) for Novartis’s Kymriah for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL) and also for adults with relapsed or refractory DLBCL who are not candidates for ASCT.
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%, respectively. There was a significant surge in FDA approvals, investors appeared more comfortable with the drug pricing controversy and innovation won the day with the FDA granting approval to gene therapies for cancer as well as a rare form of blindness.
Buyouts are the order of the day in the biotechnology sector this week, with a couple of big-name acquisitions dominating market sentiment heading into the US open on Tuesday. Celgene Corporation (NASDAQ:CELG) leads the pack with its just reported acquisition of Juno Therapeutics Inc (NASDAQ:JUNO), while Novartis AG (NYSE:NVS) announced the successful completion of a […] The post Celgene, Novartis Both Report Billion Dollar Buyouts appeared first on Market Exclusive.
Learn about the origins of Johnson & Johnson as the company turns 132 and the health care conglomerate's five largest shareholders.
Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for hegemony in a new field of oncology. Learn why this deal is important to the biotech sector.
Patent expiries and more widespread usage will fuel expected low-to-mid single digit net sales growth in Europe's generic drug market into 2020, says Moody's Investors Service in a report published today. ...
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.
Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.
JNJ stock is currently trading higher than its 50-day moving average of $141.62 and higher than its 200-day moving average of $136.52. Since Johnson & Johnson’s 3Q17 earnings release, JNJ stock has gained ~8.2%. The ongoing restructuring process in its Medical Devices business, new product launches, and its attractive product pipeline are expected by some to further boost investor sentiment and trigger a stock price rise.
Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform Lutathera® (lutetium Lu 177 dotatate), with a US PDUFA date of January ...
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free research report on Novartis AG (NYSE: NVS ). If you want access to this report all you need to do is sign up now ...